{"id":772857,"date":"2023-07-26T22:50:50","date_gmt":"2023-07-27T02:50:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/"},"modified":"2023-07-26T22:50:50","modified_gmt":"2023-07-27T02:50:50","slug":"bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/","title":{"rendered":"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement<\/b><\/p>\n<p>HERCULES, Calif., &amp; VENLO, the Netherlands&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nBio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20230726552882\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230726552882\/en\/<\/a><\/p>\n<p>\nThe settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each company mutual rights to their respective digital PCR technologies.<\/p>\n<p><b>About Bio-Rad<\/b><\/p>\n<p>\nBio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,300 employees and $2.8 billion in revenues in 2022. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fbio-rad.com&amp;esheet=53484444&amp;newsitemid=20230726552882&amp;lan=en-US&amp;anchor=bio-rad.com&amp;index=1&amp;md5=c53851fbd67fe3bc01fb21e27fdab2ca\">bio-rad.com<\/a>.<\/p>\n<p><b>About QIAGEN<\/b><\/p>\n<p>\nQIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&amp;D and industrial applications, primarily forensics). In 2022, QIAGEN had net sales of more than $2.1 billion and over 6,200 employees. Further information can be found at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Feur02.safelinks.protection.outlook.com%2F%3Furl%3Dhttp%253A%252F%252Fwww.qiagen.com%252F%26data%3D05%257C01%257Cjohn.gilardi%2540qiagen.com%257C50512daf001e41a88e1108db8c4e9a44%257Cdc81d03c239c4fd5a96f18a58773c86c%257C0%257C0%257C638258041460097766%257CUnknown%257CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%257C3000%257C%257C%257C%26sdata%3D%252FjAZPMl8w7sBYWsGyHT1eZDcdKM%252BEWzsDl%252BUGpQtOms%253D%26reserved%3D0&amp;esheet=53484444&amp;newsitemid=20230726552882&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.qiagen.com&amp;index=2&amp;md5=c53e800ea53248b77bb57c67d8c5ab0c\">http:\/\/www.qiagen.com<\/a><i>.<\/i><\/p>\n<p><i>BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.<\/i><\/p>\n<p><i>QIAGEN is a trademark of QIAGEN N.V. in certain jurisdictions.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230726552882r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230726552882\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230726552882\/en\/<\/a><\/span><\/p>\n<p><b>Bio-Rad Investor Contact:<br \/>\n<\/b><br \/>Edward Chung<br \/>\n<br \/>510-741-6104<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@bio-rad.com\">ir@bio-rad.com<br \/>\n<\/a><\/p>\n<p><b>Bio-Rad Media Contact:<br \/>\n<\/b><br \/>Anna Gralinska<br \/>\n<br \/>510-741-6643<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cc@bio-rad.com\">cc@bio-rad.com<br \/>\n<\/a><\/p>\n<p><b>QIAGEN Investor Contact:<br \/>\n<br \/><\/b>John Gilardi<br \/>\n<br \/>+49 2103 29 11711<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@qiagen.com\">ir@qiagen.com<br \/>\n<\/a><\/p>\n<p><b>QIAGEN Media Contact:<br \/>\n<\/b><br \/>Thomas Theuringer<br \/>\n<br \/>+49 2103 29 11826<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:pr@qiagen.com\">pr@qiagen.com<\/a><\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p><b>KEYWORDS:<\/b> California Europe United States Netherlands North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Stem Cells Medical Supplies Biotechnology Diabetes Health Pharmaceutical Medical Devices Research Genetics Science Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230726552882\/en\/618489\/3\/Logo_RGB_on_transpar.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230726552882\/en\/1851185\/3\/qiagen-logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement HERCULES, Calif., &amp; VENLO, the Netherlands&#8211;(BUSINESS WIRE)&#8211; Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230726552882\/en\/ The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each company mutual rights to their respective digital PCR technologies. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-772857","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement HERCULES, Calif., &amp; VENLO, the Netherlands&#8211;(BUSINESS WIRE)&#8211; Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230726552882\/en\/ The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each company mutual rights to their respective digital PCR technologies. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of &hellip; Continue reading &quot;Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-27T02:50:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230726552882r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement\",\"datePublished\":\"2023-07-27T02:50:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/\"},\"wordCount\":391,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230726552882r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/\",\"name\":\"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230726552882r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-07-27T02:50:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230726552882r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230726552882r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/","og_locale":"en_US","og_type":"article","og_title":"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement - Market Newsdesk","og_description":"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement HERCULES, Calif., &amp; VENLO, the Netherlands&#8211;(BUSINESS WIRE)&#8211; Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230726552882\/en\/ The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each company mutual rights to their respective digital PCR technologies. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of &hellip; Continue reading \"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-27T02:50:50+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230726552882r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement","datePublished":"2023-07-27T02:50:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/"},"wordCount":391,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230726552882r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/","name":"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230726552882r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-07-27T02:50:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230726552882r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230726552882r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bio-rad-and-qiagen-announce-patent-settlement-and-cross-licensing-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/772857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=772857"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/772857\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=772857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=772857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=772857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}